AN2 Therapeutics Reports Q3 2025 Financial Results and Recent Business Highlights, Including Progress in Oral AN2-502998 for Chagas Disease and Oncology Programs
ByAinvest
Wednesday, Nov 12, 2025 4:03 pm ET1min read
ANTX--
AN2 Therapeutics reported Q3 2025 financial results, highlighting progress in its pipeline for infectious diseases and oncology. The company is advancing a Phase 1 clinical trial for oral AN2-502998 for Chagas disease and planning a Phase 2 proof-of-concept study. Two lead oncology programs are expected to enter development in 2026, and AN2 has entered a collaboration with GSK focused on TB, supported by the Gates Foundation.
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue
ABOUT US
Our StoryNews AuthorsKnowledge BasePrivacy PolicyTerm of UseThird Party Brokerage DisclaimerAIME Terms of UseAInvest AI Risk DisclosuresCareersCONTACT US
Email: support@ainvest.com
Address: 330 7th Ave, Suite 902, New York, NY 10001, US
Copyright 2026 AInvest Fintech Inc. All rights reserved.
Comments
No comments yet